Savara (SVRA) Stock Price, News & Analysis

Company Overview

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. In addition, Savara has in-licensed Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor originally developed by AstraZeneca, which is being evaluated in clinical trials for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. These programs reflect the company’s strategy of leveraging existing pharmacological data to streamline development in orphan respiratory indications.

Founded in 2013 and headquartered in Austin, Texas, Savara conducts its research and development activities primarily in North America and Europe. The company collaborates with academic institutions, patient advocacy groups and strategic partners to support clinical trial execution, regulatory interactions and eventual commercialization planning. Savara’s management team brings together expertise in drug development, regulatory affairs and respiratory medicine, all aimed at transforming care for patients with life-threatening pulmonary disorders.

Key Stats

• Today's Range: $4.82 to $5.28
• 50-Day Range: $4.85 to $6.07
• 52-Week Range: $1.89 to $7.01
• Volume: 1.53 million shs
• Average Volume: 1.17 million shs
• Market Capitalization: $1.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.13
• Consensus Rating: Moderate Buy

Savara Stock Analysis - MarketRank™

Savara scored higher than 51% of companies evaluated by MarketBeat, and ranked 546th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Savara has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Savara has a consensus price target of $9.13, representing about 73.1% upside from its current price of $5.27.

Amount of Analyst Coverage

Savara has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Savara are expected to grow in the coming year, from ($0.51) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Savara is -9.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Savara is -9.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Savara has a P/B Ratio of 5.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.24% of the float of Savara has been sold short.

Short Interest Ratio / Days to Cover

Savara has a short interest ratio ("days to cover") of 20.89, which indicates bearish sentiment.

Change versus previous month

Short interest in Savara has recently decreased by 0.15%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Savara does not currently pay a dividend.

Dividend Growth

Savara does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Savara has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Savara this week, compared to 8 articles on an average week.

Search Interest

5 people have searched for SVRA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

2 people have added Savara to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Savara insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.30% of the stock of Savara is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 5/14/2026
• H.C. Wainwright 4th Annual BioConnect Investor Conference: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SVRA
• Previous Symbol: AMEX:ANX
• CIK: 1160308
• Web: www.savarapharma.com
• Phone: 512-614-1848
• Fax: 858-552-0876
• Employees: 20
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Savara: $9.13
• High Price Target: $11.00
• Low Price Target: $2.00
• Potential Upside/Downside: +73.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$118.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -92.93%
• Return on Assets: -69.60%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 11.85
• Quick Ratio: 11.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 5.27

Miscellaneous

• Outstanding Shares: 204,920,000
• Free Float: 194,061,000
• Market Cap: $1.08 billion
• Optionable: Optionable
• Beta: 0.28